Plasmodium heme biosynthesis and heme-binding proteins

Plasmodium parasites, which cause malaria, rely on a complex network of proteins to manage, synthesize, and detoxify heme. During blood-stage infection, parasites digest vast amounts of host hemoglobin, releasing toxic free heme. To survive, they convert free heme into inert hemozoin via proteins such as Heme Detoxification Protein (HDP). The parasite also has a complete heme biosynthetic pathway with enzymes (e.g., ALAS, FC, HOS) spanning the mitochondrion, cytoplasm, and apicoplast. While de novo heme biosynthesis in Plasmodium is dispensable for asexual blood-stage growth, it is essential in mosquito and liver stages, and contributes to severe disease (such as cerebral malaria). The HO-like protein PfHO is essential for apicoplast maintenance and gene expression, but diverges from classic heme oxygenases by lacking heme-degrading activity. Other malarial proteins, such as MFP, have putative metal (iron, heme) binding functions and represent novel therapeutic targets. Drug therapies for malaria often target these heme-related pathways: quinoline drugs prevent conversion of free heme to hemozoin, causing toxic buildup, while newer compounds (e.g., griseofulvin) target the parasite’s own synthetic machinery. Safety concerns include risks of oxidative damage, hemolysis, and possible impacts on host mitochondria due to off-target drug effects. Biomarkers such as hemozoin levels and parasite gene expression are used to monitor drug efficacy and infection severity. Because this entry combines a large class of targets rather than a specific canonical target, new standardized forms should be created for individual proteins such as HDP, PfHO, HOS, and MFP for structured data curation.

Other names

Heme Detoxification Protein (HDP)Plasmodium heme oxygenase (PfHO)Malarial ferrous protein (MFP)Heme O synthase (HOS)Plasmodium heme biosynthesis enzymes (including aminolevulinate synthetase [ALAS], ferrochelatase [FC])

Inhibition of heme polymerization into hemozoin, leading to toxic free heme accumulation (quinolines, artemisinins) Inhibition of heme biosynthetic enzymes, compromising parasite viability (griseofulvin, inabenfide, uniconazole–P) Potential stabilization or destabilization of metal-binding proteins (future directions, e.g., for MFP)